cdm_name,result_type,group_name,group_level,strata_name,strata_level,variable,variable_level,variable_type,estimate_type,estimate
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Number subjects,NA,numeric,count,60032
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Number records,NA,NA,count,60032
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort start date,NA,date,q05,2018-02-03
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort start date,NA,date,q25,2018-08-29
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort start date,NA,date,median,2019-07-18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort start date,NA,date,q75,2020-08-03
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort start date,NA,date,q95,2021-08-27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort end date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort end date,NA,date,q05,2018-05-06
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort end date,NA,date,q25,2019-03-09
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort end date,NA,date,median,2020-03-18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort end date,NA,date,q75,2021-06-10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Sex,Female,categorical,count,30539
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Sex,Female,categorical,percentage,50.8712020255864
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Sex,Male,categorical,count,29493
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Sex,Male,categorical,percentage,49.1287979744136
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age,NA,numeric,min,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age,NA,numeric,q05,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age,NA,numeric,q25,53
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age,NA,numeric,median,62
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age,NA,numeric,q75,71
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age,NA,numeric,q95,82
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age,NA,numeric,max,84
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age,NA,numeric,mean,61.6184201759062
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age,NA,numeric,sd,13.0377814158812
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Prior observation,NA,numeric,q05,386
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Prior observation,NA,numeric,q25,502
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Prior observation,NA,numeric,median,733
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Prior observation,NA,numeric,q75,1079
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Prior observation,NA,numeric,q95,1573
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Prior observation,NA,numeric,max,1825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Prior observation,NA,numeric,mean,823.12519989339
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Prior observation,NA,numeric,sd,377.289653295727
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Future observation,NA,numeric,q05,52
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Future observation,NA,numeric,q25,238
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Future observation,NA,numeric,median,484
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Future observation,NA,numeric,q75,867
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Future observation,NA,numeric,q95,1428
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Future observation,NA,numeric,max,1641
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Future observation,NA,numeric,mean,588.633378864606
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Future observation,NA,numeric,sd,424.544650479932
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,0 to 19,categorical,count,253
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,0 to 19,categorical,percentage,0.421441897654584
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,20 to 39,categorical,count,2841
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,20 to 39,categorical,percentage,4.73247601279318
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,40 to 59,categorical,count,22338
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,40 to 59,categorical,percentage,37.2101545842217
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,60 to 79,categorical,count,28264
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,60 to 79,categorical,percentage,47.0815565031983
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,80 to 150,categorical,count,6336
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Age group,80 to 150,categorical,percentage,10.5543710021322
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,88
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,30.4155617004264
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,32.9997473473118
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,952
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,1.58582089552239
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,8650
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,14.4089818763326
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,5348
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,8.90858208955224
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,1101
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,1.83402185501066
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,3080
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,5.13059701492537
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,9628
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,16.0381130063966
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,1199
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,1.99726812366738
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,1466
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,2.44203091684435
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,494
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.822894456289979
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,11849
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,19.7378065031983
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,3295
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,5.48873933901919
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,3089
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,5.14558901918977
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,17716
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,29.5109275053305
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,473
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.787913113006397
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,7186
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,11.9702825159915
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Copd,binary,count,4720
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,7.86247334754797
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,6013
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,10.0163246268657
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,1707
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,2.84348347547974
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,12727
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,21.2003598081023
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,62
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.103278251599147
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,37157
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,61.8953224946695
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,8324
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,13.8659381663113
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,5773
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,9.61653784648188
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,475
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0.791244669509595
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,3503
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,5.83522121535181
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Diuretics,binary,count,4366
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,7.27278784648188
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,10572
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,17.6106076759062
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Opioids,binary,count,6390
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Opioids,binary,percentage,10.6443230277186
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,4684
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,7.8025053304904
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,5189
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,8.64372334754797
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,5215
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,8.68703358208955
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,5526
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,9.20509061833689
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,2980
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,4.96401918976546
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antidepressants,binary,count,4705
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,7.83748667377399
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,3637
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,6.0584355010661
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,1165
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,1.94063166311301
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,4517
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,7.52432036247335
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,398
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.662979744136461
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,11714
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,19.5129264392324
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,269
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,Overall,Overall,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.448094349680171
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Number subjects,NA,numeric,count,253
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Number records,NA,NA,count,253
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort start date,NA,date,min,2018-01-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort start date,NA,date,q05,2018-01-22
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort start date,NA,date,q25,2018-05-24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort start date,NA,date,median,2018-12-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort start date,NA,date,q75,2019-08-20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort start date,NA,date,q95,2021-02-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort start date,NA,date,max,2021-11-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort end date,NA,date,min,2018-02-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort end date,NA,date,q05,2018-05-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort end date,NA,date,q25,2018-11-17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort end date,NA,date,median,2019-07-12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort end date,NA,date,q75,2020-04-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort end date,NA,date,q95,2021-10-12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Sex,Female,categorical,count,135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Sex,Female,categorical,percentage,53.3596837944664
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Sex,Male,categorical,count,118
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Sex,Male,categorical,percentage,46.6403162055336
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age,NA,numeric,min,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age,NA,numeric,q05,3
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age,NA,numeric,q25,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age,NA,numeric,median,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age,NA,numeric,q75,17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age,NA,numeric,q95,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age,NA,numeric,max,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age,NA,numeric,mean,12.4940711462451
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age,NA,numeric,sd,5.15676513077392
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Prior observation,NA,numeric,min,366
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Prior observation,NA,numeric,q05,386
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Prior observation,NA,numeric,q25,463
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Prior observation,NA,numeric,median,610
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Prior observation,NA,numeric,q75,811
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Prior observation,NA,numeric,q95,1269.6
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Prior observation,NA,numeric,max,1777
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Prior observation,NA,numeric,mean,694.268774703557
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Prior observation,NA,numeric,sd,298.080617379963
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Future observation,NA,numeric,min,3
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Future observation,NA,numeric,q05,63.8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Future observation,NA,numeric,q25,259
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Future observation,NA,numeric,median,470
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Future observation,NA,numeric,q75,716
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Future observation,NA,numeric,q95,1243.4
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Future observation,NA,numeric,max,1476
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Future observation,NA,numeric,mean,516.177865612648
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Future observation,NA,numeric,sd,326.84809706612
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,0 to 19,categorical,count,253
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,0 to 19,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,100.2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,250
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,27.3517786561265
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,33.3178351887559
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,7.11462450592885
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,26
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,10.2766798418972
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,2.76679841897233
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,26
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,10.2766798418972
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,37
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,14.6245059288538
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,1.97628458498024
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,56
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,22.1343873517787
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,4.74308300395257
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Copd,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,1.97628458498024
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,23
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,9.09090909090909
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,67
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,26.4822134387352
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,32
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,12.6482213438735
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,3.55731225296443
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,6.32411067193676
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Diuretics,binary,count,9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,3.55731225296443
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,55
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,21.7391304347826
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Opioids,binary,count,28
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Opioids,binary,percentage,11.0671936758893
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,4.34782608695652
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,6.71936758893281
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,26
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,10.2766798418972
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,11.8577075098814
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antidepressants,binary,count,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,2.76679841897233
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,2.76679841897233
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,6
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,2.37154150197628
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,7.5098814229249
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,54
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,21.3438735177866
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,0 to 19,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Number subjects,NA,numeric,count,2841
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Number records,NA,NA,count,2841
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort start date,NA,date,min,2018-01-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort start date,NA,date,q05,2018-02-07
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort start date,NA,date,q25,2018-08-06
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort start date,NA,date,median,2019-04-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort start date,NA,date,q75,2020-05-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort start date,NA,date,q95,2021-08-23
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort end date,NA,date,min,2018-01-22
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort end date,NA,date,q05,2018-04-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort end date,NA,date,q25,2018-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort end date,NA,date,median,2019-10-20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort end date,NA,date,q75,2020-11-20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Sex,Female,categorical,count,1135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Sex,Female,categorical,percentage,39.9507215769095
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Sex,Male,categorical,count,1706
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Sex,Male,categorical,percentage,60.0492784230905
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age,NA,numeric,min,20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age,NA,numeric,q05,24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age,NA,numeric,q25,31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age,NA,numeric,median,35
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age,NA,numeric,q75,38
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age,NA,numeric,q95,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age,NA,numeric,max,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age,NA,numeric,mean,33.8240056318198
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age,NA,numeric,sd,4.77146753106089
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Prior observation,NA,numeric,q05,386
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Prior observation,NA,numeric,q25,479
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Prior observation,NA,numeric,median,657
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Prior observation,NA,numeric,q75,913
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Prior observation,NA,numeric,q95,1402
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Prior observation,NA,numeric,max,1823
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Prior observation,NA,numeric,mean,737.423090461105
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Prior observation,NA,numeric,sd,320.223794677895
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Future observation,NA,numeric,q05,37
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Future observation,NA,numeric,q25,183
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Future observation,NA,numeric,median,405
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Future observation,NA,numeric,q75,710
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Future observation,NA,numeric,q95,1297
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Future observation,NA,numeric,max,1625
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Future observation,NA,numeric,mean,489.080957409363
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Future observation,NA,numeric,sd,379.546017445952
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,20 to 39,categorical,count,2841
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,20 to 39,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,71
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,465
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,24.4632171770503
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,28.829564772959
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,0.246392115452306
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,217
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,7.63815557902147
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,277
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,9.75008799718409
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,0.668778599084829
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,69
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,2.42872228088701
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,463
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,16.2970784934882
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,0.563181978176698
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.703977472720873
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,718
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,25.2727912706793
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,0.703977472720873
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,0.457585357268567
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,722
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,25.4135867652235
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.38718760999648
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,58
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,2.04153467089053
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Copd,binary,count,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,0.668778599084829
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,99
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,3.48468848996832
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,23
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,0.809574093629004
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,426
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,14.9947201689546
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.175994368180218
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,1050
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,36.9588173178458
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,356
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,12.5307990144315
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,254
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,8.94051390355509
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,121
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,4.25906370996128
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,144
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,5.06863780359028
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Diuretics,binary,count,144
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,5.06863780359028
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,620
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,21.8233016543471
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Opioids,binary,count,295
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Opioids,binary,percentage,10.3836677226329
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,134
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,4.71664906722985
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,253
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,8.90531502991904
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,296
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,10.4188665962689
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,286
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,10.0668778599085
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,48
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,1.68954593453009
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antidepressants,binary,count,256
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,9.01091165082717
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,102
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,3.59028511087645
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,29
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,1.02076733544527
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,239
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,8.41253079901443
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.563181978176698
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,679
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,23.9000351988736
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,20 to 39,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,1.3727560718057
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Number subjects,NA,numeric,count,22338
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Number records,NA,NA,count,22338
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort start date,NA,date,q05,2018-02-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort start date,NA,date,q25,2018-07-26
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort start date,NA,date,median,2019-04-22
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort start date,NA,date,q75,2020-04-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort start date,NA,date,q95,2021-08-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort end date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort end date,NA,date,q05,2018-04-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort end date,NA,date,q25,2019-01-06
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort end date,NA,date,median,2019-12-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort end date,NA,date,q75,2021-01-10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Sex,Female,categorical,count,10387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Sex,Female,categorical,percentage,46.4992389649924
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Sex,Male,categorical,count,11951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Sex,Male,categorical,percentage,53.5007610350076
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age,NA,numeric,min,40
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age,NA,numeric,q05,42
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age,NA,numeric,q25,48
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age,NA,numeric,median,53
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age,NA,numeric,q75,57
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age,NA,numeric,q95,59
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age,NA,numeric,max,59
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age,NA,numeric,mean,52.0055958456442
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age,NA,numeric,sd,5.29992385250369
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Prior observation,NA,numeric,q05,385
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Prior observation,NA,numeric,q25,484
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Prior observation,NA,numeric,median,671
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Prior observation,NA,numeric,q75,947
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Prior observation,NA,numeric,q95,1496
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Prior observation,NA,numeric,max,1825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Prior observation,NA,numeric,mean,761.068045483033
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Prior observation,NA,numeric,sd,343.135193546023
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Future observation,NA,numeric,q05,44
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Future observation,NA,numeric,q25,206
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Future observation,NA,numeric,median,458
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Future observation,NA,numeric,q75,853
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Future observation,NA,numeric,q95,1416
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Future observation,NA,numeric,max,1640
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Future observation,NA,numeric,mean,564.509266720387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Future observation,NA,numeric,sd,427.526117476665
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,40 to 59,categorical,count,22338
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,40 to 59,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,34
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,79
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,748
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,26.9000358134121
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,30.4572132670593
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,168
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,0.75208165457964
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,2510
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,11.2364580535411
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,1832
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,8.20127137613036
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,307
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,1.37433969021399
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,656
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,2.93669979407288
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,3469
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,15.5295908317665
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,226
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,1.01172889247023
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,32
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,0.14325364849136
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,159
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.711791565941445
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,4680
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,20.9508460918614
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,409
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,1.8309606947802
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,200
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,0.895335303071
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,6381
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,28.5656728444803
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,119
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.532724505327245
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,1065
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,4.76766048885308
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Copd,binary,count,877
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,3.92604530396634
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,960
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,4.2976094547408
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,313
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,1.40119974930612
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,3960
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,17.7276390008058
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,29
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.129823618945295
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,11602
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,51.9384009311487
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,3026
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,13.5464231354642
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,2231
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,9.98746530575701
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,245
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,1.09678574626198
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,1265
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,5.66299579192408
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Diuretics,binary,count,1320
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,5.9092130002686
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,4296
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,19.2318023099651
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Opioids,binary,count,2524
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Opioids,binary,percentage,11.299131524756
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,1346
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,6.02560658966783
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,1788
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,8.00429760945474
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,2154
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,9.64276121407467
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,2003
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,8.96678306025607
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,676
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,3.02623332437998
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antidepressants,binary,count,1792
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,8.02220431551616
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,1062
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,4.75423045930701
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,339
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,1.51759333870535
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,1779
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,7.96400752081655
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,144
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.64464141821112
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,4670
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,20.9060793267079
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,145
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,40 to 59,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.649118094726475
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Number subjects,NA,numeric,count,28264
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Number records,NA,NA,count,28264
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort start date,NA,date,q05,2018-02-03
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort start date,NA,date,q25,2018-09-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort start date,NA,date,median,2019-09-17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort start date,NA,date,q75,2020-09-11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort start date,NA,date,q95,2021-09-07
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort end date,NA,date,min,2018-01-09
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort end date,NA,date,q05,2018-05-22
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort end date,NA,date,q25,2019-04-27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort end date,NA,date,median,2020-05-09
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort end date,NA,date,q75,2021-08-23
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Sex,Female,categorical,count,15191
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Sex,Female,categorical,percentage,53.7468157373337
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Sex,Male,categorical,count,13073
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Sex,Male,categorical,percentage,46.2531842626663
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age,NA,numeric,min,60
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age,NA,numeric,q05,60
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age,NA,numeric,q25,63
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age,NA,numeric,median,67
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age,NA,numeric,q75,72
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age,NA,numeric,q95,78
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age,NA,numeric,max,79
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age,NA,numeric,mean,67.8922303990943
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age,NA,numeric,sd,5.62753670500292
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Prior observation,NA,numeric,q05,386
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Prior observation,NA,numeric,q25,509
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Prior observation,NA,numeric,median,754
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Prior observation,NA,numeric,q75,1115
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Prior observation,NA,numeric,q95,1592
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Prior observation,NA,numeric,max,1825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Prior observation,NA,numeric,mean,842.010755731673
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Prior observation,NA,numeric,sd,383.903026877337
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Future observation,NA,numeric,q05,57
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Future observation,NA,numeric,q25,254
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Future observation,NA,numeric,median,511
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Future observation,NA,numeric,q75,889
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Future observation,NA,numeric,q95,1441
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Future observation,NA,numeric,max,1641
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Future observation,NA,numeric,mean,607.376202943674
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Future observation,NA,numeric,sd,427.19969781694
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,60 to 79,categorical,count,28264
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,60 to 79,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,22
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,41
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,91
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,31.5499929238607
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,33.6533238160919
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,485
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,1.715963770167
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,4364
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,15.4401358618738
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,2599
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,9.19544296631758
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,586
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,2.07330880271724
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,1518
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,5.37078969714124
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,4553
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,16.1088310217945
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,648
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,2.29266911972828
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,503
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,1.77964902349278
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,244
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.863288989527314
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,5229
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,18.5005660911407
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,1581
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,5.59368808378149
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,1880
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,6.65157090291537
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,8494
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,30.0523634305123
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,302
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,1.06849702802151
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,4189
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,14.820973676762
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Copd,binary,count,2757
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,9.7544579677328
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,3060
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,10.8264930653835
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,811
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,2.86937446928956
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,6477
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,22.9160769883951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.0955278799886782
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,19033
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,67.3400792527597
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,4098
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,14.4990093405038
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,2735
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,9.67662043589018
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,86
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0.304273988112086
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,1692
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,5.98641381262383
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Diuretics,binary,count,2190
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,7.74837248797056
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,4790
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,16.9473535239174
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Opioids,binary,count,2988
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Opioids,binary,percentage,10.5717520520804
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,2374
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,8.39937729974526
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,2566
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,9.07868666855364
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,2335
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,8.26139258420606
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,2673
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,9.45726011887914
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,1590
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,5.62553071044438
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antidepressants,binary,count,2138
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,7.56439286725163
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,1916
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,6.77894140956694
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,625
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,2.21129351825644
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,2122
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,7.50778375318426
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,210
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.742994622134164
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,5291
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,18.7199264081517
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,74
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,60 to 79,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.261817152561562
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Number subjects,NA,numeric,count,6336
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Number records,NA,NA,count,6336
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort start date,NA,date,q05,2018-02-06
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort start date,NA,date,q25,2018-12-17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort start date,NA,date,median,2020-01-17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort start date,NA,date,q75,2021-01-10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort start date,NA,date,q95,2021-08-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort start date,NA,date,max,2021-12-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort end date,NA,date,min,2018-01-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort end date,NA,date,q05,2018-06-12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort end date,NA,date,q25,2019-07-08
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort end date,NA,date,median,2020-10-12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort end date,NA,date,q75,2021-11-23
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Sex,Female,categorical,count,3691
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Sex,Female,categorical,percentage,58.2544191919192
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Sex,Male,categorical,count,2645
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Sex,Male,categorical,percentage,41.7455808080808
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age,NA,numeric,min,80
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age,NA,numeric,q05,80
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age,NA,numeric,q25,81
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age,NA,numeric,median,82
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age,NA,numeric,q75,83
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age,NA,numeric,q95,84
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age,NA,numeric,max,84
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age,NA,numeric,mean,81.9468118686869
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age,NA,numeric,sd,1.26697319985357
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Prior observation,NA,numeric,q05,394
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Prior observation,NA,numeric,q25,631
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Prior observation,NA,numeric,median,998
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Prior observation,NA,numeric,q75,1393.25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Prior observation,NA,numeric,q95,1669
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Prior observation,NA,numeric,max,1824
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Prior observation,NA,numeric,mean,1001.23942550505
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Prior observation,NA,numeric,sd,419.347517715662
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Future observation,NA,numeric,q05,82
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Future observation,NA,numeric,q25,323
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Future observation,NA,numeric,median,545
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Future observation,NA,numeric,q75,917
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Future observation,NA,numeric,q95,1439
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Future observation,NA,numeric,max,1639
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Future observation,NA,numeric,mean,637.607007575758
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Future observation,NA,numeric,sd,412.036441681674
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,80 to 150,categorical,count,6336
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Age group,80 to 150,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,4
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,55
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,107
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,429
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,40.5405618686869
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,37.5611294982861
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,291
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,4.59280303030303
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,1541
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,24.3213383838384
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,614
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,9.69065656565657
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,187
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,2.95138888888889
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,830
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,13.0997474747475
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,1117
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,17.6294191919192
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,309
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,4.87689393939394
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,930
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,14.6780303030303
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,69
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,1.08901515151515
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,1185
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,18.7026515151515
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,1284
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,20.2651515151515
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,991
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,15.6407828282828
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,2063
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,32.5599747474747
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,41
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.64709595959596
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,1862
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,29.3876262626263
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Copd,binary,count,1064
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,16.7929292929293
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,1889
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,29.8137626262626
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,559
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,8.82260101010101
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,1841
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,29.0561868686869
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,5405
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,85.3061868686869
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,812
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,12.8156565656566
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,549
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,8.66477272727273
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,14
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0.220959595959596
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,386
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,6.09217171717172
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Diuretics,binary,count,703
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,11.0953282828283
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,811
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,12.7998737373737
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Opioids,binary,count,555
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Opioids,binary,percentage,8.7594696969697
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,819
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,12.9261363636364
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,565
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,8.91729797979798
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,404
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,6.37626262626263
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,534
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,8.4280303030303
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,665
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,10.4955808080808
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antidepressants,binary,count,512
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,8.08080808080808
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,550
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,8.68055555555556
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,166
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,2.61994949494949
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,358
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,5.65025252525253
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,26
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.410353535353535
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,1020
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,16.0984848484848
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group,80 to 150,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.110479797979798
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Number subjects,NA,numeric,count,30539
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Number records,NA,NA,count,30539
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort start date,NA,date,q05,2018-02-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort start date,NA,date,q25,2018-09-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort start date,NA,date,median,2019-08-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort start date,NA,date,q75,2020-08-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort start date,NA,date,q95,2021-08-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort end date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort end date,NA,date,q05,2018-04-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort end date,NA,date,q25,2019-03-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort end date,NA,date,median,2020-04-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort end date,NA,date,q75,2021-06-27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Sex,Female,categorical,count,30539
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Sex,Female,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Sex,Male,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Sex,Male,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age,NA,numeric,min,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age,NA,numeric,q05,41
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age,NA,numeric,q25,55
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age,NA,numeric,median,63
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age,NA,numeric,q75,73
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age,NA,numeric,q95,82
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age,NA,numeric,max,84
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age,NA,numeric,mean,62.9759651593045
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age,NA,numeric,sd,12.8536913087852
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Prior observation,NA,numeric,q05,387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Prior observation,NA,numeric,q25,506
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Prior observation,NA,numeric,median,741
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Prior observation,NA,numeric,q75,1101
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Prior observation,NA,numeric,q95,1585
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Prior observation,NA,numeric,max,1825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Prior observation,NA,numeric,mean,832.619601165723
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Prior observation,NA,numeric,sd,382.169874040115
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Future observation,NA,numeric,q05,50
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Future observation,NA,numeric,q25,239
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Future observation,NA,numeric,median,487
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Future observation,NA,numeric,q75,869
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Future observation,NA,numeric,q95,1428
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Future observation,NA,numeric,max,1641
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Future observation,NA,numeric,mean,589.869150921772
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Future observation,NA,numeric,sd,425.005630637967
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,0 to 19,categorical,count,135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,0 to 19,categorical,percentage,0.442057696715675
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,20 to 39,categorical,count,1135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,20 to 39,categorical,percentage,3.71655915386882
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,40 to 59,categorical,count,10387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,40 to 59,categorical,percentage,34.0122466354498
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,60 to 79,categorical,count,15191
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,60 to 79,categorical,percentage,49.7429516356135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,80 to 150,categorical,count,3691
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Age group,80 to 150,categorical,percentage,12.0861848783523
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,3
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,44
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,95
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,34.2393988015325
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,35.0200670163464
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,445
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,1.45715314843315
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,6474
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,21.1991224336095
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,3455
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,11.3134025344641
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,781
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,2.55738563803661
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,1659
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,5.43239791741707
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,6488
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,21.2449654540096
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,580
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,1.89921084514883
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,872
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,2.85536527063755
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,264
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.864468384688431
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,7833
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,25.6491699138806
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,1662
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,5.44222142178853
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,2829
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,9.26356462228626
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,8910
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,29.1758079832346
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,215
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.704017813287927
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,3511
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,11.4967746160647
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Copd,binary,count,2630
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,8.61193883231278
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,3030
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,9.92173941517404
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,889
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,2.91103179540915
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,7357
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,24.0905072202757
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.0327450145715315
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,18910
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,61.920822554766
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,4038
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,13.2224368839844
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,3252
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,10.648678738662
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,448
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,1.46697665280461
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,2093
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,6.85353154982154
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Diuretics,binary,count,2541
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,8.32050820262615
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,5591
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,18.3077376469433
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Opioids,binary,count,3384
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Opioids,binary,percentage,11.0809129310063
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,2500
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,8.18625364288287
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,3000
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,9.82350437145945
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,2553
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,8.35980222011199
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,3208
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,10.5046006745473
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,1442
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,4.72183110121484
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antidepressants,binary,count,2969
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,9.7219948262877
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,1912
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,6.26084678607682
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,670
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,2.19391597629261
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,2437
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,7.97996005108222
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,244
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.798978355545368
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,6098
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,19.9679098857199
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,137
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Female,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.448606699629981
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Number subjects,NA,numeric,count,29493
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Number records,NA,NA,count,29493
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort start date,NA,date,q05,2018-02-03
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort start date,NA,date,q25,2018-08-24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort start date,NA,date,median,2019-06-27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort start date,NA,date,q75,2020-07-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort start date,NA,date,q95,2021-08-24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort end date,NA,date,min,2018-01-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort end date,NA,date,q05,2018-05-14
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort end date,NA,date,q25,2019-03-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort end date,NA,date,median,2020-02-29
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort end date,NA,date,q75,2021-05-24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Sex,Female,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Sex,Female,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Sex,Male,categorical,count,29493
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Sex,Male,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age,NA,numeric,min,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age,NA,numeric,q05,38
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age,NA,numeric,q25,52
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age,NA,numeric,median,60
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age,NA,numeric,q75,69
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age,NA,numeric,q95,81
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age,NA,numeric,max,84
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age,NA,numeric,mean,60.2127284440376
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age,NA,numeric,sd,13.0782464822516
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Prior observation,NA,numeric,q05,386
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Prior observation,NA,numeric,q25,499
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Prior observation,NA,numeric,median,724
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Prior observation,NA,numeric,q75,1055
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Prior observation,NA,numeric,q95,1562
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Prior observation,NA,numeric,max,1825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Prior observation,NA,numeric,mean,813.29406977927
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Prior observation,NA,numeric,sd,371.920055139981
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Future observation,NA,numeric,q05,52
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Future observation,NA,numeric,q25,237
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Future observation,NA,numeric,median,482
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Future observation,NA,numeric,q75,863
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Future observation,NA,numeric,q95,1428
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Future observation,NA,numeric,max,1640
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Future observation,NA,numeric,mean,587.353778862781
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Future observation,NA,numeric,sd,424.070203133142
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,0 to 19,categorical,count,118
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,0 to 19,categorical,percentage,0.400094937781847
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,20 to 39,categorical,count,1706
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,20 to 39,categorical,percentage,5.78442342250704
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,40 to 59,categorical,count,11951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,40 to 59,categorical,percentage,40.5214796731428
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,60 to 79,categorical,count,13073
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,60 to 79,categorical,percentage,44.3257722171363
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,80 to 150,categorical,count,2645
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Age group,80 to 150,categorical,percentage,8.96822974943207
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,34
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,79
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,444
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,26.4561082290713
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,30.263937077495
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,507
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,1.71905197843556
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,2176
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,7.37802190350253
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,1893
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,6.41847217983928
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,320
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,1.08500322110331
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,1421
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,4.8180924287119
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,3140
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,10.6465941070763
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,619
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,2.09880310582172
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,594
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,2.01403722917302
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,230
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.779846065168006
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,4016
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,13.6167904248466
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,1633
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,5.53690706269284
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,260
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,0.881565117146441
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,8806
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,29.8579323907368
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,258
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.874783847014546
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,3675
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,12.4605838673584
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Copd,binary,count,2090
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,7.08642728783101
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,2983
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,10.1142644017224
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,818
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,2.77353948394534
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,5370
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,18.20771030414
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,52
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.176313023429288
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,18247
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,61.8689180483505
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,4286
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,14.5322618926525
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,2521
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,8.54779100125453
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0.091547146780592
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,1410
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,4.78079544298647
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Diuretics,binary,count,1825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,6.18790899535483
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,4981
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,16.8887532634863
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Opioids,binary,count,3006
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Opioids,binary,percentage,10.1922490082392
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,2184
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,7.40514698403011
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,2189
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,7.42210015935985
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,2662
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,9.02587054555318
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,2318
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,7.85949208286712
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,1538
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,5.2147967314278
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antidepressants,binary,count,1736
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,5.88614247448547
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,1725
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,5.84884548876004
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,495
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,1.67836435764419
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,2080
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,7.05252093717153
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,154
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.522157800155969
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,5616
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,19.0418065303631
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,132
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,sex,Male,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.447563828705116
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Number subjects,NA,numeric,count,135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Number records,NA,NA,count,135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort start date,NA,date,min,2018-01-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort start date,NA,date,q05,2018-01-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort start date,NA,date,q25,2018-05-07
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort start date,NA,date,median,2018-11-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort start date,NA,date,q75,2019-05-06
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort start date,NA,date,q95,2020-04-10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort start date,NA,date,max,2021-08-27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort end date,NA,date,min,2018-02-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort end date,NA,date,q05,2018-04-22
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort end date,NA,date,q25,2018-11-10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort end date,NA,date,median,2019-06-03
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort end date,NA,date,q75,2020-04-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort end date,NA,date,q95,2020-08-20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Sex,Female,categorical,count,135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Sex,Female,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Sex,Male,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Sex,Male,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age,NA,numeric,min,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age,NA,numeric,q05,3
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age,NA,numeric,q25,8.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age,NA,numeric,median,14
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age,NA,numeric,q75,18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age,NA,numeric,q95,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age,NA,numeric,max,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age,NA,numeric,mean,12.6666666666667
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age,NA,numeric,sd,5.27172123467463
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Prior observation,NA,numeric,min,366
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Prior observation,NA,numeric,q05,385.1
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Prior observation,NA,numeric,q25,455
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Prior observation,NA,numeric,median,572
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Prior observation,NA,numeric,q75,778.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Prior observation,NA,numeric,q95,1130.3
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Prior observation,NA,numeric,max,1699
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Prior observation,NA,numeric,mean,657.822222222222
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Prior observation,NA,numeric,sd,275.674501624236
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Future observation,NA,numeric,min,4
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Future observation,NA,numeric,q05,87.7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Future observation,NA,numeric,q25,351.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Future observation,NA,numeric,median,520
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Future observation,NA,numeric,q75,783
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Future observation,NA,numeric,q95,1327.7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Future observation,NA,numeric,max,1476
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Future observation,NA,numeric,mean,590.348148148148
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Future observation,NA,numeric,sd,346.316637933022
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,0 to 19,categorical,count,135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,0 to 19,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,1
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2.7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,6.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,15
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,34
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,102
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,180
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,27.3111111111111
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,32.8018625851449
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,7.40740740740741
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,9.62962962962963
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,11.8518518518519
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,14.8148148148148
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,35
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,25.9259259259259
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,5.18518518518519
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,7.40740740740741
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,15
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,11.1111111111111
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,6.66666666666667
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,5.92592592592593
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Diuretics,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,29
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,21.4814814814815
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Opioids,binary,count,15
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Opioids,binary,percentage,11.1111111111111
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,6
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,4.44444444444444
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,5.92592592592593
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,15
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,11.1111111111111
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,12.5925925925926
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,3.7037037037037
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,8.88888888888889
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,33
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,24.4444444444444
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Number subjects,NA,numeric,count,118
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Number records,NA,NA,count,118
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort start date,NA,date,min,2018-01-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort start date,NA,date,q05,2018-01-22
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort start date,NA,date,q25,2018-07-14
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort start date,NA,date,median,2019-01-18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort start date,NA,date,q75,2019-11-20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort start date,NA,date,q95,2021-03-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort start date,NA,date,max,2021-11-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort end date,NA,date,min,2018-02-14
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort end date,NA,date,q05,2018-05-08
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort end date,NA,date,q25,2018-12-28
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort end date,NA,date,median,2019-09-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort end date,NA,date,q75,2020-04-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort end date,NA,date,q95,2021-11-29
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Sex,Female,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Sex,Female,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Sex,Male,categorical,count,118
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Sex,Male,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age,NA,numeric,min,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age,NA,numeric,q05,3.85
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age,NA,numeric,q25,8.25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age,NA,numeric,median,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age,NA,numeric,q75,17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age,NA,numeric,q95,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age,NA,numeric,max,19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age,NA,numeric,mean,12.2966101694915
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age,NA,numeric,sd,5.03714293262127
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Prior observation,NA,numeric,min,366
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Prior observation,NA,numeric,q05,386
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Prior observation,NA,numeric,q25,495
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Prior observation,NA,numeric,median,661
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Prior observation,NA,numeric,q75,915.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Prior observation,NA,numeric,q95,1438.9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Prior observation,NA,numeric,max,1777
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Prior observation,NA,numeric,mean,735.966101694915
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Prior observation,NA,numeric,sd,317.881688796088
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Future observation,NA,numeric,min,3
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Future observation,NA,numeric,q05,53.25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Future observation,NA,numeric,q25,203.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Future observation,NA,numeric,median,419.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Future observation,NA,numeric,q75,594.75
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Future observation,NA,numeric,q95,923.4
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Future observation,NA,numeric,max,1391
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Future observation,NA,numeric,mean,431.322033898305
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Future observation,NA,numeric,sd,281.288758206338
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,0 to 19,categorical,count,118
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,0 to 19,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,29.75
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,95.6
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,250
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,27.3983050847458
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,34.0387260175463
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,6.77966101694915
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,11.0169491525424
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,8.47457627118644
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,14.4067796610169
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,17.7966101694915
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,4.23728813559322
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,4.23728813559322
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,11.0169491525424
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,40
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,33.8983050847458
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,14.4067796610169
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,6.77966101694915
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Diuretics,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,4.23728813559322
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,26
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,22.0338983050847
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Opioids,binary,count,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Opioids,binary,percentage,11.0169491525424
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,4.23728813559322
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,7.6271186440678
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,9.32203389830508
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,11.0169491525424
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,5.93220338983051
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,17.7966101694915
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,0 to 19 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Number subjects,NA,numeric,count,1135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Number records,NA,NA,count,1135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort start date,NA,date,min,2018-01-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort start date,NA,date,q05,2018-02-12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort start date,NA,date,q25,2018-07-29
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort start date,NA,date,median,2019-04-24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort start date,NA,date,q75,2020-04-14
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort start date,NA,date,q95,2021-08-28
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort end date,NA,date,min,2018-01-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort end date,NA,date,q05,2018-04-18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort end date,NA,date,q25,2018-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort end date,NA,date,median,2019-10-10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort end date,NA,date,q75,2020-09-25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Sex,Female,categorical,count,1135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Sex,Female,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Sex,Male,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Sex,Male,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age,NA,numeric,min,20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age,NA,numeric,q05,23
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age,NA,numeric,q25,30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age,NA,numeric,median,35
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age,NA,numeric,q75,37
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age,NA,numeric,q95,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age,NA,numeric,max,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age,NA,numeric,mean,33.2149779735683
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age,NA,numeric,sd,5.19679264252055
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Prior observation,NA,numeric,min,366
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Prior observation,NA,numeric,q05,387.7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Prior observation,NA,numeric,q25,484.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Prior observation,NA,numeric,median,659
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Prior observation,NA,numeric,q75,903
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Prior observation,NA,numeric,q95,1384
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Prior observation,NA,numeric,max,1775
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Prior observation,NA,numeric,mean,732.366519823789
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Prior observation,NA,numeric,sd,312.057700436792
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Future observation,NA,numeric,q05,31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Future observation,NA,numeric,q25,167.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Future observation,NA,numeric,median,387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Future observation,NA,numeric,q75,664.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Future observation,NA,numeric,q95,1217.3
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Future observation,NA,numeric,max,1625
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Future observation,NA,numeric,mean,461.240528634361
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Future observation,NA,numeric,sd,364.735790600603
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,20 to 39,categorical,count,1135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,20 to 39,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,4
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,42
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,86.5999999999999
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,465
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,32.8343612334802
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,35.7800312303237
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,153
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,13.4801762114537
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,153
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,13.4801762114537
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,0.969162995594714
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,2.6431718061674
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,250
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,22.0264317180617
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,6
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,0.52863436123348
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,1.14537444933921
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,370
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,32.5991189427313
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,0.616740088105727
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,0.881057268722467
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,320
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,28.1938325991189
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,6
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.52863436123348
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,32
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,2.81938325991189
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,count,9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,0.79295154185022
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,43
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,3.78854625550661
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,15
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,1.3215859030837
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,175
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,15.4185022026432
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,384
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,33.8325991189427
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,120
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,10.5726872246696
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,121
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,10.6607929515419
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,121
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,10.6607929515419
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,75
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,6.6079295154185
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Diuretics,binary,count,71
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,6.25550660792952
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,266
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,23.4361233480176
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Opioids,binary,count,128
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Opioids,binary,percentage,11.2775330396476
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,58
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,5.11013215859031
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,109
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,9.60352422907489
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,126
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,11.1013215859031
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,150
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,13.215859030837
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,1.85022026431718
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,count,122
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,10.7488986784141
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,40
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,3.52422907488987
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,1.58590308370044
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,91
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,8.01762114537445
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.969162995594714
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,275
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,24.2290748898678
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,1.05726872246696
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Number subjects,NA,numeric,count,1706
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Number records,NA,NA,count,1706
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort start date,NA,date,min,2018-01-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort start date,NA,date,q05,2018-02-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort start date,NA,date,q25,2018-08-07
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort start date,NA,date,median,2019-05-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort start date,NA,date,q75,2020-05-18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort start date,NA,date,q95,2021-08-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort start date,NA,date,max,2021-12-29
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort end date,NA,date,min,2018-01-22
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort end date,NA,date,q05,2018-04-24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort end date,NA,date,q25,2018-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort end date,NA,date,median,2019-10-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort end date,NA,date,q75,2020-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Sex,Female,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Sex,Female,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Sex,Male,categorical,count,1706
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Sex,Male,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age,NA,numeric,min,20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age,NA,numeric,q05,25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age,NA,numeric,q25,32
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age,NA,numeric,median,35
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age,NA,numeric,q75,38
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age,NA,numeric,q95,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age,NA,numeric,max,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age,NA,numeric,mean,34.2291910902696
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age,NA,numeric,sd,4.42144774552359
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Prior observation,NA,numeric,q05,386
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Prior observation,NA,numeric,q25,474
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Prior observation,NA,numeric,median,656
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Prior observation,NA,numeric,q75,926
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Prior observation,NA,numeric,q95,1422.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Prior observation,NA,numeric,max,1823
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Prior observation,NA,numeric,mean,740.787221570926
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Prior observation,NA,numeric,sd,325.590511366268
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Future observation,NA,numeric,q05,41.25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Future observation,NA,numeric,q25,195
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Future observation,NA,numeric,median,419.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Future observation,NA,numeric,q75,747
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Future observation,NA,numeric,q95,1337.25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Future observation,NA,numeric,max,1620
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Future observation,NA,numeric,mean,507.603165298945
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Future observation,NA,numeric,sd,388.087415208671
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,20 to 39,categorical,count,1706
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,20 to 39,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,6
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,55
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,233
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,18.8939038686987
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,21.3370905925843
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,64
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,3.75146541617819
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,124
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,7.26846424384525
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,0.468933177022274
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,2.28604923798359
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,213
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,12.4853458382181
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,0.586166471277843
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.41031652989449
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,348
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,20.3985932004689
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,0.762016412661196
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,402
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,23.5638921453693
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.293083235638921
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,26
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,1.52403282532239
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,count,10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,0.586166471277843
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,56
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,3.28253223915592
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,0.468933177022274
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,251
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,14.7127784290739
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.293083235638921
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,666
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,39.0386869871043
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,236
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,13.8335287221571
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,133
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,7.79601406799531
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,69
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,4.04454865181712
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Diuretics,binary,count,73
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,4.27901524032825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,354
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,20.7502930832356
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Opioids,binary,count,167
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Opioids,binary,percentage,9.78898007033998
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,76
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,4.45486518171161
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,144
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,8.44079718640094
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,170
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,9.96483001172333
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,136
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,7.97186400937866
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,1.58264947245018
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,count,134
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,7.8546307151231
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,62
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,3.63423212192263
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,0.644783118405627
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,148
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,8.67526377491208
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.293083235638921
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,404
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,23.6811254396249
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,20 to 39 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,1.58264947245018
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Number subjects,NA,numeric,count,10387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Number records,NA,NA,count,10387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort start date,NA,date,q05,2018-02-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort start date,NA,date,q25,2018-07-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort start date,NA,date,median,2019-04-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort start date,NA,date,q75,2020-05-18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort start date,NA,date,q95,2021-08-18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort start date,NA,date,max,2021-12-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort end date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort end date,NA,date,q05,2018-04-07
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort end date,NA,date,q25,2018-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort end date,NA,date,median,2019-12-08
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort end date,NA,date,q75,2021-01-16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Sex,Female,categorical,count,10387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Sex,Female,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Sex,Male,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Sex,Male,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age,NA,numeric,min,40
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age,NA,numeric,q05,42
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age,NA,numeric,q25,49
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age,NA,numeric,median,53
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age,NA,numeric,q75,57
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age,NA,numeric,q95,59
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age,NA,numeric,max,59
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age,NA,numeric,mean,52.442668720516
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age,NA,numeric,sd,5.14272147536889
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Prior observation,NA,numeric,q05,385
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Prior observation,NA,numeric,q25,481
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Prior observation,NA,numeric,median,667
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Prior observation,NA,numeric,q75,953
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Prior observation,NA,numeric,q95,1499
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Prior observation,NA,numeric,max,1824
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Prior observation,NA,numeric,mean,762.135361509579
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Prior observation,NA,numeric,sd,346.218529180881
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Future observation,NA,numeric,q05,39
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Future observation,NA,numeric,q25,198
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Future observation,NA,numeric,median,448
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Future observation,NA,numeric,q75,839
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Future observation,NA,numeric,q95,1407
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Future observation,NA,numeric,max,1640
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Future observation,NA,numeric,mean,554.428323866371
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Future observation,NA,numeric,sd,426.655950791009
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,40 to 59,categorical,count,10387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,40 to 59,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,3
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,42
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,89
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,748
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,32.6468662751516
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,33.8156764185526
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,59
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,0.568017714450756
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,1838
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,17.6951959179744
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,1130
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,10.8789833445653
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,218
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,2.0987773178011
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,342
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,3.29257726003658
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,2249
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,21.6520650813517
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,0.962741888899586
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,15
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,0.144411283334938
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,78
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.750938673341677
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,2882
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,27.7462212380861
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,169
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,1.6270337922403
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,182
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,1.75219023779725
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,3099
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,29.8353711369982
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,49
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.471743525560797
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,595
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,5.72831423895254
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,count,505
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,4.86184653894291
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,438
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,4.21680947338019
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,155
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,1.49224992779436
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,2100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,20.2175796668913
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,5235
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,50.3995378838933
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,1295
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,12.4675074612496
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,1209
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,11.639549436796
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,236
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,2.27207085780302
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,736
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,7.08578030230095
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Diuretics,binary,count,738
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,7.10503514007894
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,2140
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,20.6026764224511
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Opioids,binary,count,1291
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Opioids,binary,percentage,12.4289977856937
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,672
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,6.46962549340522
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,1008
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,9.70443824010783
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,1045
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,10.0606527390007
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,1151
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,11.0811591412342
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,315
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,3.0326369500337
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,count,1065
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,10.2532011167806
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,505
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,4.86184653894291
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,188
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,1.80995475113122
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,880
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,8.47212862231636
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,89
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.856840281120632
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,2297
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,22.1141811880235
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,74
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.712428997785694
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Number subjects,NA,numeric,count,11951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Number records,NA,NA,count,11951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort start date,NA,date,q05,2018-02-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort start date,NA,date,q25,2018-07-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort start date,NA,date,median,2019-04-16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort start date,NA,date,q75,2020-04-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort start date,NA,date,q95,2021-08-11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort end date,NA,date,min,2018-01-16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort end date,NA,date,q05,2018-05-03
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort end date,NA,date,q25,2019-01-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort end date,NA,date,median,2019-12-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort end date,NA,date,q75,2021-01-03
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Sex,Female,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Sex,Female,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Sex,Male,categorical,count,11951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Sex,Male,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age,NA,numeric,min,40
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age,NA,numeric,q05,42
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age,NA,numeric,q25,48
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age,NA,numeric,median,52
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age,NA,numeric,q75,56
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age,NA,numeric,q95,59
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age,NA,numeric,max,59
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age,NA,numeric,mean,51.6257216969291
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age,NA,numeric,sd,5.40443683487211
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Prior observation,NA,numeric,q05,385
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Prior observation,NA,numeric,q25,485
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Prior observation,NA,numeric,median,674
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Prior observation,NA,numeric,q75,939.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Prior observation,NA,numeric,q95,1495.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Prior observation,NA,numeric,max,1825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Prior observation,NA,numeric,mean,760.140406660531
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Prior observation,NA,numeric,sd,340.444471279687
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Future observation,NA,numeric,q05,47
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Future observation,NA,numeric,q25,217
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Future observation,NA,numeric,median,467
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Future observation,NA,numeric,q75,864
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Future observation,NA,numeric,q95,1422
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Future observation,NA,numeric,max,1640
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Future observation,NA,numeric,mean,573.27093967032
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Future observation,NA,numeric,sd,428.106027681247
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,40 to 59,categorical,count,11951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,40 to 59,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,7
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,15
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,28
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,64
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,444
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,21.905279892896
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,26.2003142477541
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,109
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,0.912057568404318
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,672
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,5.62296042172203
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,702
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,5.87398544054891
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,89
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,0.744707555853067
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,314
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,2.62739519705464
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,1220
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,10.2083507656263
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,126
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,1.05430507907288
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,17
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,0.142247510668563
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,81
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.677767550832566
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,1798
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,15.0447661283575
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,240
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,2.00820015061501
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,0.150615011296126
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,3282
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,27.4621370596603
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,70
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.585725043929378
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,470
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,3.9327252949544
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,count,372
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,3.11271023345327
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,522
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,4.36783532758765
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,158
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,1.32206509915488
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,1860
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,15.5635511672663
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.209187515689064
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,6367
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,53.2758764956907
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,1731
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,14.4841435863108
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,1022
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,8.55158564136892
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0.0753075056480629
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,529
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,4.42640783198059
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Diuretics,binary,count,582
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,4.8698853652414
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,2156
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,18.0403313530249
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Opioids,binary,count,1233
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Opioids,binary,percentage,10.3171282737846
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,674
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,5.63969542297716
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,780
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,6.52665048949879
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,1109
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,9.27955819596686
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,852
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,7.12911053468329
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,361
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,3.02066772655008
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,count,727
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,6.08317295623797
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,557
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,4.66069784955234
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,151
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,1.26349259476194
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,899
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,7.52238306417873
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,55
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.46021253451594
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,2373
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,19.8560789892059
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,71
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,40 to 59 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.594092544556941
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Number subjects,NA,numeric,count,15191
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Number records,NA,NA,count,15191
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort start date,NA,date,q05,2018-02-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort start date,NA,date,q25,2018-09-28
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort start date,NA,date,median,2019-10-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort start date,NA,date,q75,2020-09-25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort start date,NA,date,q95,2021-09-08
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort end date,NA,date,min,2018-01-11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort end date,NA,date,q05,2018-05-14
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort end date,NA,date,q25,2019-04-28
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort end date,NA,date,median,2020-05-28
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort end date,NA,date,q75,2021-08-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Sex,Female,categorical,count,15191
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Sex,Female,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Sex,Male,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Sex,Male,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age,NA,numeric,min,60
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age,NA,numeric,q05,60
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age,NA,numeric,q25,63
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age,NA,numeric,median,68
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age,NA,numeric,q75,73
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age,NA,numeric,q95,78
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age,NA,numeric,max,79
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age,NA,numeric,mean,68.2338884866039
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age,NA,numeric,sd,5.61824823641884
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Prior observation,NA,numeric,q05,387
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Prior observation,NA,numeric,q25,514
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Prior observation,NA,numeric,median,759
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Prior observation,NA,numeric,q75,1123
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Prior observation,NA,numeric,q95,1600
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Prior observation,NA,numeric,max,1825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Prior observation,NA,numeric,mean,849.294253176223
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Prior observation,NA,numeric,sd,387.06770324056
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Future observation,NA,numeric,q05,57
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Future observation,NA,numeric,q25,257
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Future observation,NA,numeric,median,512
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Future observation,NA,numeric,q75,892
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Future observation,NA,numeric,q95,1442
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Future observation,NA,numeric,max,1641
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Future observation,NA,numeric,mean,608.995128694622
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Future observation,NA,numeric,sd,427.293629636053
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,60 to 79,categorical,count,15191
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,60 to 79,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,3
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,25
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,44
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,96
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,951
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,34.0414060957146
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,35.0630776992874
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,223
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,1.46797445856099
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,3342
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,21.9998683430979
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,1761
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,11.5923902310579
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,422
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,2.77796063458627
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,830
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,5.46376143769337
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,3199
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,21.0585214929893
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,316
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,2.08017905338687
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,274
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,1.80369955894938
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,135
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.88868408926338
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,3693
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,24.3104469751827
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,800
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,5.26627608452373
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,1742
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,11.4673161740504
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,4347
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,28.6156276742808
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,137
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.901849779474689
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,2038
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,13.4158383253242
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,count,1530
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,10.0717530116516
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,1548
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,10.1902442235534
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,405
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,2.66605226779014
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,3935
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,25.9034954907511
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.0329142255282733
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,10108
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,66.5393983279573
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,2142
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,14.1004542163123
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,1584
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,10.427226647357
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,73
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0.48054769271279
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,1029
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,6.77374761371865
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Diuretics,binary,count,1321
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,8.69593838456981
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,2686
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,17.6815219537884
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Opioids,binary,count,1621
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Opioids,binary,percentage,10.6707919162662
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,1271
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,8.36679612928708
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,1529
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,10.065170166546
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,1166
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,7.67559739319334
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,1580
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,10.4008952669344
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,785
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,5.16753340793891
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,count,1443
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,9.49904548745968
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,1032
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,6.79349614903561
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,353
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,2.3237443222961
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,1228
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,8.08373378974393
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,128
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.842604173523797
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,2892
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,19.0375880455533
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,44
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.289645184648805
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Number subjects,NA,numeric,count,13073
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Number records,NA,NA,count,13073
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort start date,NA,date,q05,2018-02-03
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort start date,NA,date,q25,2018-09-12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort start date,NA,date,median,2019-08-27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort start date,NA,date,q75,2020-08-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort start date,NA,date,q95,2021-09-02
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort start date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort end date,NA,date,min,2018-01-09
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort end date,NA,date,q05,2018-05-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort end date,NA,date,q25,2019-04-24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort end date,NA,date,median,2020-04-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort end date,NA,date,q75,2021-08-11
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Sex,Female,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Sex,Female,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Sex,Male,categorical,count,13073
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Sex,Male,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age,NA,numeric,min,60
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age,NA,numeric,q05,60
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age,NA,numeric,q25,63
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age,NA,numeric,median,66
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age,NA,numeric,q75,72
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age,NA,numeric,q95,78
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age,NA,numeric,max,79
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age,NA,numeric,mean,67.4952191539815
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age,NA,numeric,sd,5.61245848706766
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Prior observation,NA,numeric,q05,386
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Prior observation,NA,numeric,q25,507
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Prior observation,NA,numeric,median,750
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Prior observation,NA,numeric,q75,1107
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Prior observation,NA,numeric,q95,1583.4
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Prior observation,NA,numeric,max,1825
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Prior observation,NA,numeric,mean,833.547234758663
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Prior observation,NA,numeric,sd,380.032009527076
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Future observation,NA,numeric,q05,57
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Future observation,NA,numeric,q25,250
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Future observation,NA,numeric,median,509
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Future observation,NA,numeric,q75,885
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Future observation,NA,numeric,q95,1441
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Future observation,NA,numeric,max,1640
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Future observation,NA,numeric,mean,605.494989673373
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Future observation,NA,numeric,sd,427.099155873092
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,60 to 79,categorical,count,13073
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,60 to 79,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,80 to 150,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Age group,80 to 150,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,2
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,20
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,37
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,83
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,440
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,28.6549376577679
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,31.6933488554276
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,262
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,2.00413065095999
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,1022
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,7.8176394094699
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,838
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,6.41015834162013
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,164
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,1.2544939952574
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,688
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,5.26275529717739
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,1354
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,10.3572248145032
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,332
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,2.53958540503327
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,229
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,1.75170198118259
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,109
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,0.833779545628394
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,1536
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,11.7494071750937
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,781
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,5.97414518473189
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,138
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,1.05561080088733
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,4147
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,31.7218695020271
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,165
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,1.26214334888702
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,2151
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,16.453759657309
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,count,1227
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,9.38575690354165
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,1512
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,11.5658226879829
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,406
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,3.10563757362503
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,2542
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,19.4446569264897
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,22
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0.168285779851603
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,8925
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,68.2704811443433
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,1956
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,14.9621356995334
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,1151
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,8.80440602769066
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0.0994415971850379
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,663
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,5.07152145643693
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Diuretics,binary,count,869
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,6.6472883041383
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,2104
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,16.0942400367169
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Opioids,binary,count,1367
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Opioids,binary,percentage,10.4566664116882
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,1103
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,8.43723705346898
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,1037
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,7.93237971391417
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,1169
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,8.94209439302379
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,1093
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,8.3607435171728
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,805
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,6.15772967184273
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,count,695
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,5.31630077258472
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,884
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,6.76202860858257
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,272
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,2.08062418725618
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,894
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,6.83852214487876
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,82
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.6272469976287
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,2399
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,18.3507993574543
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,60 to 79 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,0.229480608888549
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Number subjects,NA,numeric,count,3691
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Number records,NA,NA,count,3691
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort start date,NA,date,q05,2018-02-06
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort start date,NA,date,q25,2018-12-24
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort start date,NA,date,median,2020-01-10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort start date,NA,date,q75,2021-01-07
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort start date,NA,date,q95,2021-09-06
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort start date,NA,date,max,2021-12-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort end date,NA,date,min,2018-01-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort end date,NA,date,q05,2018-06-19
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort end date,NA,date,q25,2019-07-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort end date,NA,date,median,2020-10-12
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort end date,NA,date,q75,2021-11-28
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Sex,Female,categorical,count,3691
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Sex,Female,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Sex,Male,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Sex,Male,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age,NA,numeric,min,80
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age,NA,numeric,q05,80
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age,NA,numeric,q25,81
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age,NA,numeric,median,82
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age,NA,numeric,q75,83
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age,NA,numeric,q95,84
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age,NA,numeric,max,84
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age,NA,numeric,mean,81.9699268490924
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age,NA,numeric,sd,1.26637372310531
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Prior observation,NA,numeric,q05,394.5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Prior observation,NA,numeric,q25,632
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Prior observation,NA,numeric,median,984
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Prior observation,NA,numeric,q75,1381
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Prior observation,NA,numeric,q95,1674
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Prior observation,NA,numeric,max,1824
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Prior observation,NA,numeric,mean,999.566242210783
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Prior observation,NA,numeric,sd,417.963416454418
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Future observation,NA,numeric,q05,89
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Future observation,NA,numeric,q25,325
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Future observation,NA,numeric,median,573
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Future observation,NA,numeric,q75,961
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Future observation,NA,numeric,q95,1436
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Future observation,NA,numeric,max,1639
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Future observation,NA,numeric,mean,650.424546193443
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Future observation,NA,numeric,sd,414.578132699698
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,80 to 150,categorical,count,3691
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Age group,80 to 150,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,4
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,15
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,54
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,109
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,429
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,40.2213492278515
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,37.3114488618932
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,159
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,4.30777567054999
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,1131
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,30.6421024112707
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,398
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,10.7829856407478
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,129
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,3.49498780818206
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,454
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,12.3001896505012
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,774
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,20.9699268490924
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,158
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,4.28068274180439
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,583
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,15.7951774586833
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,37
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,1.0024383635871
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,868
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,23.5166621511785
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,686
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,18.5857491194798
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,892
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,24.1668924410729
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,1109
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,30.0460579788675
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,23
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.62313736114874
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,839
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,22.7309672175562
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,count,584
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,15.8222703874289
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,1001
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,27.120021674343
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,314
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,8.50717962611758
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,1137
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,30.8046599837442
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,3156
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,85.5052831211054
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,466
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,12.6253047954484
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,335
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,9.07613112977513
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,9
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0.243836358710377
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,245
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,6.63776754267136
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Diuretics,binary,count,407
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,11.0268219994581
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,470
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,12.7336765104308
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Opioids,binary,count,329
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Opioids,binary,percentage,8.91357355730154
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,493
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,13.3568138715795
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,346
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,9.3741533459767
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,201
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,5.44567867786508
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,310
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,8.39880791113519
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,320
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,8.66973719859117
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,count,334
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,9.04903820102953
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,331
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,8.96775941479274
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,107
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,2.89894337577892
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,226
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,6.12300189650501
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.433486859929558
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,601
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,16.282850176104
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and female,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,NA
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Number subjects,NA,numeric,count,2645
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Number records,NA,NA,count,2645
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort start date,NA,date,min,2018-01-01
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort start date,NA,date,q05,2018-02-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort start date,NA,date,q25,2018-12-07
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort start date,NA,date,median,2020-01-27
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort start date,NA,date,q75,2021-01-13
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort start date,NA,date,q95,2021-08-26
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort start date,NA,date,max,2021-12-30
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort end date,NA,date,min,2018-01-05
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort end date,NA,date,q05,2018-06-04
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort end date,NA,date,q25,2019-06-21
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort end date,NA,date,median,2020-10-10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort end date,NA,date,q75,2021-11-18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort end date,NA,date,q95,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Cohort end date,NA,date,max,2021-12-31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Sex,Female,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Sex,Female,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Sex,Male,categorical,count,2645
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Sex,Male,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age,NA,numeric,min,80
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age,NA,numeric,q05,80
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age,NA,numeric,q25,81
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age,NA,numeric,median,82
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age,NA,numeric,q75,83
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age,NA,numeric,q95,84
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age,NA,numeric,max,84
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age,NA,numeric,mean,81.9145557655955
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age,NA,numeric,sd,1.26734406116646
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Prior observation,NA,numeric,min,365
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Prior observation,NA,numeric,q05,394
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Prior observation,NA,numeric,q25,628
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Prior observation,NA,numeric,median,1018
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Prior observation,NA,numeric,q75,1408
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Prior observation,NA,numeric,q95,1662
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Prior observation,NA,numeric,max,1824
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Prior observation,NA,numeric,mean,1003.57429111531
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Prior observation,NA,numeric,sd,421.339407859811
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Future observation,NA,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Future observation,NA,numeric,q05,75
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Future observation,NA,numeric,q25,317
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Future observation,NA,numeric,median,514
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Future observation,NA,numeric,q75,857
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Future observation,NA,numeric,q95,1444
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Future observation,NA,numeric,max,1638
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Future observation,NA,numeric,mean,619.720604914934
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Future observation,NA,numeric,sd,407.868445559526
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,0 to 19,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,0 to 19,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,20 to 39,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,20 to 39,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,40 to 59,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,40 to 59,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,60 to 79,categorical,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,60 to 79,categorical,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,80 to 150,categorical,count,2645
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Age group,80 to 150,categorical,percentage,100
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,min,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q05,4
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q25,16
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,median,31
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q75,55
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,q95,104.8
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,max,388
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,mean,40.986011342155
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Visits in prior year count from -365 to -1,Visit occurrence,numeric,sd,37.9093815724102
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,count,132
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Myocardial infarction,binary,percentage,4.99054820415879
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,count,410
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Hypothyroidism,binary,percentage,15.5009451795841
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,count,216
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Asthma,binary,percentage,8.16635160680529
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,count,58
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Rheumatoid arthritis,binary,percentage,2.19281663516068
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,count,376
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Pneumonia,binary,percentage,14.2155009451796
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,count,343
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Depressive disorder,binary,percentage,12.9678638941399
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,count,151
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Venous thromboembolism,binary,percentage,5.70888468809074
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,count,347
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Dementia,binary,percentage,13.1190926275992
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,count,32
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Inflammarory bowel disease,binary,percentage,1.20982986767486
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,count,317
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Anxiety,binary,percentage,11.9848771266541
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,count,598
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Heart failure,binary,percentage,22.6086956521739
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,count,99
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Osteoporosis,binary,percentage,3.74291115311909
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,count,954
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Diabetes,binary,percentage,36.0680529300567
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,count,18
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Chronic liver disease,binary,percentage,0.680529300567108
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,count,1023
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Malignant neoplastic disease,binary,percentage,38.6767485822306
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,count,480
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Copd,binary,percentage,18.1474480151229
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,count,888
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Chronic kidney disease,binary,percentage,33.5727788279773
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,count,245
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Stroke,binary,percentage,9.26275992438563
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,count,704
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Gerd,binary,percentage,26.6162570888469
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,count,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Hiv,binary,percentage,0
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,count,2249
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Conditions any time prior flag from any time prior to -1,Hypertension,binary,percentage,85.0283553875236
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,count,346
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Agents renin ang sys,binary,percentage,13.0812854442344
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,count,214
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Psycholeptics,binary,percentage,8.09073724007562
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,count,5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Hormonal contraceptices syst,binary,percentage,0.189035916824197
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,count,141
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antiepileptics,binary,percentage,5.33081285444234
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Diuretics,binary,count,296
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Diuretics,binary,percentage,11.1909262759924
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,count,341
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antiinflammatory antirheumatic,binary,percentage,12.8922495274102
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Opioids,binary,count,226
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Opioids,binary,percentage,8.54442344045369
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,count,326
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Beta blocking agents,binary,percentage,12.3251417769376
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,count,219
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Drugs acid related disorder,binary,percentage,8.27977315689981
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,count,203
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Drugs used in diabetes,binary,percentage,7.67485822306238
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,count,224
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Drugs obstructive airway dis,binary,percentage,8.46880907372401
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,count,345
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antithrombotics,binary,percentage,13.0434782608696
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,count,178
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antidepressants,binary,percentage,6.7296786389414
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,count,219
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Calicum channel blockers,binary,percentage,8.27977315689981
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,count,59
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antineoplastic agents,binary,percentage,2.23062381852552
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,count,132
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Lipid modifying agents,binary,percentage,4.99054820415879
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,count,10
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Immunosupressants,binary,percentage,0.378071833648393
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,count,419
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Antibacterials systemic,binary,percentage,15.8412098298677
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,count,<5
PHARMETRICS,Summary characteristics,cohort_name,Simvastatin,age_group and sex,80 to 150 and male,Medications prior year flag from -365 to -1,Psychostimulants,binary,percentage,NA
